About Contraline
Contraline is a Healthcare company based in Charlottesville (United States) founded in 2015 by Kevin Eisenfrats. Contraline is focused on developing innovative male contraception solutions. It operates on a HealthTech model. Contraline has raised $111.12 million across 13 funding rounds from investors including HHS, Afton Scientific and Google Ventures. The company has 7 employees. Its chief executive, as recorded, is Kevin Eisenfrats. Its website contraline.com draws about 15 thousand monthly visits. Contraline offers products and services including ADAM™. Its focus areas include Medical Devices and Contraceptive Devices. Its legal entity is Contraline, Inc. Its competitors include Kitotech Medical, microMend and Alafair Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Contraline is engaged in the development of male contraception technologies. The company is based in the healthcare sector, specifically targeting medical devices for contraception. Their flagship product, ADAM, is designed as the worlds first implant for long-lasting and reversible male contraception, comparable to an IUD for men. Clinical trials for this investigational device have been initiated, marking a significant advancement in male contraceptive options since the vasectomy.
- Headquarters Charlottesville, United States
- Employees 7
- Founders Kevin Eisenfrats
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website contraline.com
- Social LinkedIn X Facebook
- Legal Name Contraline, Inc.
- Total Equity Funding$111.12M (USD)
in 13 rounds
- Latest Funding Round$92.5M (USD), Series B
Jun 2026
- InvestorsHHS
& 21 more
- Employee Count7
Products & Services of Contraline
Contraline offers a comprehensive portfolio of products and services, including ADAM™.
An implant is developed for long-lasting male contraception.
Funding Insights of Contraline
Contraline has successfully raised a total of $111.12M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $92.5 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $111.12M
- Total Rounds 13
- Last Round Series B — $92.5M
- First Round $10,000
(Jun 2015)
- Investors Count 22
Latest 10 of 13 funding rounds of Contraline with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $92.5M | Series B | – | BVF Partners, RA Capital Management | |
| Sep 2024 | $291,440 | Grant | – | – | |
| Nov 2022 | $7.2M | Series A | – | Google Ventures | |
| Sep 2022 | Series A | – | – | ||
| Oct 2021 | $10.7M | Series A | – | MBX Capital | |
| Jul 2021 | Series A | – | Rhia Ventures | – | |
| Jun 2016 | $50,000 | Grant | – | – | |
| Jun 2016 | $700,000 | Seed | – | – | |
| Jun 2016 | $20,000 | Grant | – | – | – |
| May 2016 | $20,000 | Seed | – | – |
22 investors in total: 20 institutional and 2 angel.
Investors in Contraline
Contraline has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Afton Scientific and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Investments are focused on reproductive healthcare startups by Rhia Ventures. | rhiaventures.org | San Francisco, United States | ||
| shangbaycapital.com | ||||
Venture capital investments are focused on women's health and sexual wellbeing. | amboystreet.vc | |||
Healthcare sector investments are managed by MBX Capital. | mbxcapital.com | New York, United States | ||
US early-stage tech startups are funded by Graphene Ventures. | graphenevc.com | Palo Alto, United States | ||
Metaplanet is recognized as an evergreen investment firm focused on deep tech. | metaplanet.com | Tallinn, Estonia | ||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Smith Ventures is involved in unspecified business activities. | smithventures.com | |||
Early-stage VC firm funding companies in the US | cit.org | Herndon, United States |
Investor details for Contraline
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Contraline
21 people are tracked at Contraline (8 in leadership, 7 in board & advisors, 6 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Kevin Eisenfrats | Co-Founder & CEO | Leadership |
Alex Pastuszak | Chief Medical Officer | Leadership |
Yelena Tropsha | Chief Technology Officer | Leadership |
Tim Barry | Director Of Engineering And Product Transfer | Leadership |
Robert Greenleaf | VP, Quality & Operations | Leadership |
Ted Looney | Director of Finance & Business Development | Leadership |
Paul Turek | Chief Scientific Advisor | Leadership |
Lindsey Ott | Director of Program Management | Leadership |
Tom Thorpe | Director | Board & advisors |
Gurdane Bhutani | Director | Board & advisors |
Martin Emerson | Director | Board & advisors |
Craig Niederberger | Scientific Advisor | Board & advisors |
Jay Sandlow | Scientific Advisor | Board & advisors |
Aaron Spitz | Scientific Advisor | Board & advisors |
Meng Deng | Director | Board & advisors |
Nic Matsumoto | Senior Principal Scientist & CMC Manager | Team |
Doug Conner | Engineering Consultant, R&d | Team |
Sean Lavin M.d. | Business Development And Investor Relations | Team |
Ernest Anoma | Senior Design Assurance Engineer | Team |
Kyle Ripley | Operations Manager | Team |
1 more people are available in the full profile.
Complete people profiles for Contraline
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Contraline
3 dated milestones of Contraline across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Contraline is founded.
- Funding First funding round of $10K.
- Funding Latest funding round, Series B, of $92.5M.
Competitors of Contraline
Contraline has 3 listed competitors in our database, 3 of them funded. They include Kitotech Medical, microMend and Alafair Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kitotechmedical.com | 2011 | Seattle, United States | $20.85M | Developer of a device to close wounds, lacerations, and surgical incisions | ||
| micromendskinclosure.com | 2017 | Seattle, United States | $3.41M | Solutions for treating dermatological disorders are provided by microMend. | ||
| alafairbiosciences.com | 2011 | Austin, United States | $13.74M | Biomaterials and devices for internal wound healing are developed. |
Detailed competitors of Contraline
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Contraline
The website of Contraline (contraline.com) receives about 14.9K visits a month.
- Monthly visits14.9K
▼ 30.9% vs previous month
Websites whose visitors overlap most with Contraline. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
jamesdysonaward.org | jamesdysonaward.org | 100% | #504,541 | – |
Top companies in Genitourinary Disorders
3 companies that operate in the same segment as Contraline (Genitourinary Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Contraline
Complete news archive for Contraline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Contraline
Contraline was founded in 2015.
Contraline is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Kevin Eisenfrats is the CEO of Contraline, as recorded in our data. They have also founded this company.
Contraline is a funded company, having raised a total of $111.12M across 13 funding rounds to date. The company's 1st funding round was a Seed of $20K, raised on Jun 2015.
Contraline has 7 employees.
Contraline is engaged in the development of male contraception technologies. The company is based in the healthcare sector, specifically targeting medical devices for contraception. Their flagship product, ADAM, is designed as the worlds first implant for long-lasting and reversible male contraception, comparable to an IUD for men. Clinical trials for this investigational device have been initiated, marking a significant advancement in male contraceptive options since the vasectomy.
Contraline's top competitors include Kitotech Medical, Alafair Biosciences and microMend.
Contraline offers ADAM™.
Contraline has 22 investors. Key investors include HHS, Afton Scientific, Google Ventures, Rhia Ventures, and ShangBay Capital.
Contraline operates through Contraline, Inc..